

Supplemental Tables for:
Sustained CA19-9 response to neoadjuvant chemotherapy in borderline resectable pancreatic cancer predicts progression and survival

J. Bart Rose et al.

Table S1: ROC curve criterion

Percent change in CA19-9 from baseline to minimum value							Percent change in CA19-9 from minimum to final value						
Criterion	Sensitivity	95% CI	Specificity	95% CI	+LR	-LR	Criterion	Sensitivity	95% CI	Specificity	95% CI	+LR	-LR
<0	0	0.0 - 9.0	100	94.5 - 100.0		1	≥0	100	91.0 - 100.0	0	0.0 - 5.5	1	
≤40	17.95	7.5 - 33.5	98.46	91.7 - 100.0	11.67	0.83	>5	97.44	86.5 - 99.9	24.62	14.8 - 36.9	1.3	0.1
≤44	23.08	11.1 - 39.3	96.92	89.3 - 99.6	7.5	0.79	>14	92.31	79.1 - 98.4	26.15	16.0 - 38.5	1.3	0.3
≤45	25.64	13.0 - 42.1	95.38	87.1 - 99.0	5.56	0.78	>20	89.74	75.8 - 97.1	29.23	18.6 - 41.8	1.3	0.4
≤58	35.9	21.2 - 52.8	93.85	85.0 - 98.3	5.83	0.68	>22	87.18	72.6 - 95.7	33.85	22.6 - 46.6	1.3	0.4
≤64	38.46	23.4 - 55.4	90.77	81.0 - 96.5	4.17	0.68	>27	84.62	69.5 - 94.1	40	28.0 - 52.9	1.4	0.4
≤67	41.03	25.6 - 57.9	89.23	79.1 - 95.6	3.81	0.66	>28	82.05	66.5 - 92.5	41.54	29.4 - 54.4	1.4	0.4
≤73	51.28	34.8 - 67.6	87.69	77.2 - 94.5	4.17	0.56	>33	79.49	63.5 - 90.7	50.77	38.1 - 63.4	1.6	0.4
≤77	53.85	37.2 - 69.9	84.62	73.5 - 92.4	3.5	0.55	>36	74.36	57.9 - 87.0	52.31	39.5 - 64.9	1.6	0.5
≤78*	58.97	42.1 - 74.4	83.08	71.7 - 91.2	3.48	0.49	>37	71.79	55.1 - 85.0	53.85	41.0 - 66.3	1.6	0.5
≤84	61.54	44.6 - 76.6	73.85	61.5 - 84.0	2.35	0.52	>39	69.23	52.4 - 83.0	55.38	42.5 - 67.7	1.6	0.6
≤87	66.67	49.8 - 80.	66.15	53.4 - 77.	1.97	0.5	>47	66.67	49.8 - 80.	64.62	51.8 - 76.	1.9	0.5

		9		4					9		1			
≤89	71.79	55.1 - 85. 0	63.08	50.2 - 74. 7	1.9 4	0. 45		>53	56.41	39.6 - 72. 2	66.15	53.4 - 77. 4	1. 7	0. 7
≤91	76.92	60.7 - 88. 9	61.54	48.6 - 73. 3	2	0. 37		>58	53.85	37.2 - 69. 9	70.77	58.2 - 81. 4	1. 8	0. 7
≤93	82.05	66.5 - 92. 5	50.77	38.1 - 63. 4	1.6 7	0. 35		>63	51.28	34.8 - 67. 6	78.46	66.5 - 87. 7	2. 4	0. 6
≤94	84.62	69.5 - 94. 1	41.54	29.4 - 54. 4	1.4 5	0. 37		>66 *	48.72	32.4 - 65. 2	83.08	71.7 - 91. 2	2. 9	0. 6
≤95	87.18	72.6 - 95. 7	40	28.0 - 52. 9	1.4 5	0. 32		>72	35.9	21.2 - 52. 8	84.62	73.5 - 92. 4	2. 3	0. 8
≤96	92.31	79.1 - 98. 4	35.38	23.9 - 48. 2	1.4 3	0. 22		>73	33.33	19.1 - 50. 2	86.15	75.3 - 93. 5	2. 4	0. 8
≤98	94.87	82.7 - 99. 4	20	11.1 - 31. 8	1.1 9	0. 26		>77	30.77	17.0 - 47. 6	89.23	79.1 - 95. 6	2. 9	0. 8
≤99	97.44	86.5 - 99. 9	3.08	0.4 - 10. 7	1.0 1	0. 83		>84	17.95	7.5 - 33. 5	90.77	81.0 - 96. 5	1. 9	0. 9
≤100	100	91.0 - 100 .0	0	0.0 - 5.5	1			>92	5.13	0.6 - 17. 3	93.85	85.0 - 98. 3	0. 8	1
								>99	0	0.0 - 9.0	100	94.5 - 100 .0		1

* Youden index J

Table S2: Type of adjuvant therapy by response group

CA19-9 Response Group	CRT	FOLFIRI	FOLFIRINOX	FOLFOX	GemDoc	GemAbx	IROX	VM	Capecitabine	Observation
1	0	1	0	1	0	0	0	0	1	1
2	2	3	1	0	2	0	1	1	0	0
3	0	2	0	1	0	1	0	4	0	1
4	9	2	4	0	3	0	1	13	0	10
Total	11	8	5	2	5	1	2	18	1	12
Treatment timeframe	2011-17	2013-16	2011-16	2011	2011-17	2016	2012-13	2010-16	2010	2011-17

CRT = XRT, Fluoropyrimidine (5FU or capecitabine)

FOLFIRI = 5-fluorouracil, Leucovorin, Irinotecan

FOLFIRINOX = 5-fluorouracil, Leucovorin, Irinotecan, Oxaliplatin

FOLFOX = 5-fluorouracil, Leucovorin, Oxaliplatin

GD = Gemcitabine, Docetaxel

GA = Gemcitabine, Abraxane

IROX = Irinotecan, Oxaliplatin

VM = XRT, Interferon, cisplatin, 5-fluorouracil